This review offers a concise summary of the most recent experimental advances in vascular development using the mouse as a model organism.
INTRODUCTION
Efforts in experimental research during the last two years have continued to seek molecular information to better explain the morphogenesis of the vasculature, its plasticity and ability to provide unique functions to specific organs. We have identified five areas where the use of the mouse model has particularly excelled in our understanding of vascular development. In this review, we summarize the highlights in these areas and place the latest advancements in the context of existent knowledge.
HEMOGENIC ENDOTHELIUM: THE ORIGIN OF DEFINITIVE HEMATOPOIETIC CELLS
Endothelial and hematopoietic lineages are spatially and chronologically linked at the onset of development [1] . This close relationship has long prompted the hypothesis that hematopoietic and endothelial cells emerge from a common progenitor: the hemangioblast [2] . However, blood emergence has been observed in close contact or 'budding' from endothelium in a number of vascular beds including the dorsal aorta, the aorta-gonad-mesonephros region (AGM), the vitelline artery and the placenta [3] . These observations elicited the historical speculation that a subset of endothelial cells hold hematopoietic potential (hemogenic endothelium). During the last four years, a preponderance of experimental evidence supports the notion that definitive hematopoietic stem cells (HSC) do in fact originate from a specialized endothelium with temporally restricted hemogenic capacity [3] [4] [5] [6] [7] . In-vitro work further verifies that hematopoietic cells originate from an endothelial intermediate.
Live culture imaging of mouse flk-1 and hemangioblasts derived from embryonic stem cells demonstrate an endothelial stage prior to HSC emergence. Cultured hemangioblasts first generate phenotypically defined endothelial cells, which then begin to express hematopoietic transcription factors, such as Runx1. Subsequent culture of these Runx1 and endothelial cells results in the emergence of rounded cells with hematopoietic markers [6] . Importantly, in human tissues, hematopoietic cells in the AGM were found to co-express vascular endothelial (VE)-cadherin and CD45, showing concurrent endothelial and hematopoietic traits [5] .
Curiously, the hemogenic capacity of endothelial cells is limited to specific vascular beds, and temporally restricted to a narrow developmental window. This begs the question: how is this endothelium specified to such a remarkable function? Whereas the full answer to this question remains incomplete, lineage tracing experiments revealed that all hemogenic endothelium of the embryo originates from the lateral plate mesoderm (Hox6B positive), whereas nonhemogenic endothelium does not express Hox6B [8 & ]. Furthermore, hemogenic endothelium lineage restriction has been shown to rely on the expression of Runx1 and absence of HoxA3 (Fig. 1) 
COORDINATED SIGNALING OF MULTIPLE PATHWAYS IN ENDOTHELIAL CELLS
Understanding the regulation of concurrent operational signaling pathways has been a challenging problem to tackle, as the integration of signaling inputs and outputs is difficult to trace. Nonetheless, recent advances have shed light on how signaling interplay is able to finely tune cellular output.
Ephrins are transmembrane ligands that interact with Eph receptors and mediate bidirectional signaling: 'reverse' signaling via the cytoplasmic PDZ domain [domain found in postsynaptic density protein (PSD95), Drosophila disc large tumor suppressor (Dlg1), and zonula occludens-1 protein (zo-1)] of ephrin and 'forward' signaling into the Eph receptor tyrosine kinase. EphrinB2 is specific to arterial endothelium and required for developmental angiogenesis, though its mechanism of action has been mysterious. Mutations in the PDZ domain of ephrinB2 result in a reduction of vascular sprouting and filopodia extensions, whereas overexpression of ephrinB2 increases filopodia and motility to such an extent that mature vasculature formation is compromised [10, 11] . EphrinB2 protein was found to be concentrated on filopodia of tip cells [11] . This is consistent with the hypothesis that ephrinB2 regulates the directional response to a growth-factor gradient, such as vascular endothelial growth factor (VEGF). The effects of ephrinB2 on the VEGF
KEY POINTS
Hematopoietic stem cells are derived from hemogenic endothelium. Hemogenic potential of the endothelium relies on expression of Runx1 and suppression of HoxA3.
Cross interactions of distinct signaling pathways such as Ephrin-B2/VEGF or VEGF/ERK1/2 can significantly change cellular output.
Endothelial cell polarity has emerged as a necessary precondition for vascular lumen formation.
Vascular diseases that first present in adulthood, such as cerebral cavernous malformations and brain arteriovenus malformations, often have origins in developmental defects.
Heterotypic cell interactions have emerged as critical regulators of vascular morphogenesis and organspecific differentiation.
Non-hemogenic endothelium
Hemogenic endothelium HoxA3 Runx1 FIGURE 1. Hemogenic potential of the dorsal aorta. The endothelium of the dorsal aorta is derived from the lateral plate mesoderm. This endothelium, however, contains two functionally distinct regions: the hemogenic endothelium (ventral) and nonhemogenic endothelium (dorsal). HoxA3 expression suppresses the hemogenic capacity of endothelium, whereas the hematopoietic transcription factor Runx1 induces hematopoiesis.
receptors VEGFR2 and VEGFR3 were assessed in vitro and in vivo. It was found that when ephrinB2 is compromised (by absence or disruption of PDZ signaling) VEGF receptors are not properly endocytosed, which in turn reduces signaling output [10, 11] . These experiments suggest that because of its location, ephrinB2 may be critical in offering precise spatial control of VEGF-receptor activity. Induction of collateral arterial growth remains a critical problem in heart and limb ischemia, particularly as these vessels are poorly responsive to growth factor stimulation. It has been proposed that defective activation of extracellular-signal-regulated kinase (ERK) might be the common denominator of this impaired arteriogenesis [12 && ]. This conclusion was reached by following signaling pathways downstream in a synectin-null mouse model that displays defects in arterial morphogenesis [13] . Lack of synectin is accompanied by a reduced response to VEGF and ERK1/2 activation. Furthermore, it was found that arterial defects due to either synectin inactivation or LDL receptor and ApoB48 mutations can be almost completely corrected by enhancing ERK1/2 activation in vitro or in vivo [12 && ]. This work demonstrates that ERK1/2 signaling is a key regulator of arterial growth, and that growth factor-resistant vessels can instead respond to downstream enhancement of ERK1/2.
Notch1 signaling has been shown to coordinate the ratio of tip and stalk cells during vascular sprouting. More recently, VEGFR3 was found to positivelyregulate Notch signaling [14] . Endothelial ablation of VEGFR3 resembles a Notch inactivation phenotype that is typified by overabundance of tip cells [14] . This phenomenon is due to a passive VEGFR3 signaling mechanism, as antibody blockade of VEGFR3 or ligand ablation does not recapitulate the knockout phenotype [14] .
The contribution of microRNAs (miRs) to the regulation of vascular development is largely unknown and in fact, the prevalence of miR upregulation in disease states implies that these molecules are early responders triggered to maintain homeostasis. Nonetheless, novel contributions of miRs during the neoangiogenic process have been revealed in the past few years [15] [16] [17] [18] . More recently, miR-181 was found to regulate Prox1, a transcription factor required for lymphatic endothelial cell specification. miR-181 is highly expressed in the vasculature, but significantly reduced in lymphatic endothelial cells, reciprocally to Prox1 expression [19 && ]. Forced expression of miR-181 in embryonic lymphatic endothelium reduced lymphatic markers and induced vascular endothelial markers. This data suggests miR-181 is crucial for lymphatic/endothelial lineage divergence [19 && ].
Although endogenous miR-181 expression was examined in vivo, a miR-181-null mouse model would conclusively reveal the biological relevance of the miR regulation to vascular and lymphatic development.
LUMEN FORMATION
Successful lumenization of vessels requires concurrent changes in endothelial cytoskeleton, cell-cell adhesion and cell-matrix adhesion. Current findings suggest these events hinge upon the formation and maintenance of endothelial cell polarity. b1 Integrin has emerged as a novel regulator of endothelial cell polarity and lumen formation in the developing vasculature [20 & ,21] . Conditional loss of b1 integrin in endothelial cells generated lumenal obstructions in multiple vascular beds of the mouse embryo. Cell-tracing experiments revealed that the occlusions consisted of cuboidal endothelial cells that were aberrantly adherent to neighboring cells in all directions. The phenotype ultimately resulted in embryonic lethality between E14.5-17.5 [19 && ]. Supporting these findings, the cell-polarity protein Par3 was downregulated in the absence of b1 integrin. Multiple adhesion proteins including VE-cadherin, CD99 and platelet endothelial cell adhesion molecule (PECAM) were found to be mislocalized on those endothelial cells lacking the integrin [19 && ]. The findings are consistent with a previously considered role for b1 integrin in the cell polarity of epidermal cells [22, 23] .
Further insight on lumen formation was gained from research on the novel endothelium-restrictive small GTPase Rasip1 [24] . Genetic inactivation of Rasip1 results in lethality by E10.5 [25 && ], with phenotypes that strikingly resemble the polarity defects observed in b1 integrin deletion mutants [20 & ]. Rasip1 mutants exhibited severe vascular remodeling defects and displayed poor blood flow due to occluded lumens in multiple vascular beds [25 && ]. Rasip1 and its newly described binding partner Arhgap29 affected the activation, though not levels, of b1 integrin [25 && ]. The data indicates that Rasip1 is upstream of the b1 integrin pathway and in this way contributes to the regulation of endothelial polarity (Fig. 2) .
In addition to molecular signaling events, mechanical forces are important for launching successful lumenization. For a brief period before lumenization, cords of endothelial cells form transient apical cell-cell contacts wherein the lumen eventually emerges. It has been observed that in the time preceding lumenization, the CD34 sialomucin (podocalyxin/gp135) accumulates on this apical/ cell-cell contact face in the mouse aorta [26 & ].
Because the CD34 sialomucin is decorated with a large number of negatively charged sialic acids, it was hypothesized that lumenization depends on CD34-driven electrostatic repulsion between the adjacent membranes (Fig. 2) . Enzymatic removal of the negative charge and subsequent wholeembryo culture yield failure of aorta lumenization, whereas restoration of the negative charge by injection of dextran sulfate rescued lumenization [26 & ]. This study provides a mechanical explanation for the breakdown of cell-cell adhesion in the emerging cord, though it is surprisingly not sufficient for lumenization. Xu et al. [25 && ] observed that, despite failure to lumenize, CD34 is correctly localized between endothelial cells in Rasip1 mutant mice. This suggests that the electrostatic force generated by CD34 localization is necessary, but not sufficient to drive lumen formation.
The formation of lumenized vessels requires a three-dimensional matrix that appears to trigger signaling events that initiate the process of tubulogenesis [27] . Furthermore, it has long been recognized that fibroblasts are required in culture to drive vascular lumen formation, however the specific molecules responsible were only identified recently [28] . Fibroblast-secreted factors were shown to significantly stiffen the matrix gel surrounding sprouting endothelial cells; this is predicted to facilitate lumen formation by providing mechanical strength to endothelial cells necessary for adherence [28] .
Closely regulating the size and shape (if not directly the genesis) of lumens, Notch has been shown to act cell autonomously in endothelial cells [29] . Notch was linked to lumen size and vessel patterning in gain-of-function and loss-of-function mutants. Overexpression of activated Notch4 in the endothelium leads to dilated vessels and death at E10.5. Conditional inactivation of endothelial Notch4 or Notch1 results in smaller lumens and mortality at E9.5 [30] . Similar findings were also documented more recently in an endothelialspecific (recombination signal binding protein for immunoglobulin kappa J region) knockout model [31] .
VASCULAR DISEASES WITH DEVELOPMENTAL ROOTS
Cerebral cavernous malformations (CCMs) are vascular lesions located in the central nervous system and are characterized by an abundant number of vascular tufts with extremely thin walls [32] . Using standard linkage analysis, three genes (CCM1, CCM2 and CCM3) were initially identified as hereditary causative components for the disease, albeit functional information on these proteins was absent [33] . More recently, somatic mutations have been shown to cooperate with germline CCM mutations to result in loss of heterozygosity and, ultimately, manifestation of the disease [34, 35] . These discoveries together with the generation of a homozygous mutant mouse and mutant cells have shed light on how CCM proteins function to provide structural stability to the endothelial lining.
Inactivation of both copies of either CCM1 or CCM2 in mice results in early embryonic lethality, though heterozygous animals show no phenotype, possibly because mice do not live long enough to experience a second somatic mutation [36] . To model the two-hit mutation hypothesis, McDonald et al. [37 && ] crossed CCM1 heterozygotes with a mismatch repair-deficient background. Imposition of genetic instability was sufficient to facilitate a second-hit mutation and resulted in animals that recapitulated most hallmarks of CCM disease. An alternative mouse model for CCM was created by inducing deletion of CCM at several stages postbirth. Tamoxifen-induced deletion at P1 generates CCM-like lesions in the cerebellum and retina a week postinduction [38] . Interestingly, deletion in adult animals did not yield CCM lesions. This suggests that CCM disease progression may, in fact, be dependent on active angiogenesis, which in humans could occur due to age-related hypoxic events [38] .
Although endothelial depletion of CCM proteins has been shown to cause lesions, an endothelial nonautonomous effect of CCM3 deletion was also reported. Deletion of CCM3 in various nonendothelial cell types of the central nervous system yield broadly spread embryonic lethality [39] . Gfapcre ablation of CCM3 led to an abundance of astrocytes accompanied by dilated, simplified vessels in the brain. About two-thirds of these mice developed CCM-like lesions. Together, the data favors an alternative mechanism of CCM formation based on paracrine signaling.
Another recent development that has contributed to our understanding of hereditary vascular disorders has been in the area of brain arteriovenus malformations (BAVMs). BAVMs are often lethal vascular lesions composed of abnormal arteries and veins. Because BAVMs exhibit no clinical manifestation until adulthood, it is unclear whether they represent a developmental defect or an adult disorder. Abnormal transforming growth factor (TGF)-b signaling has been associated with BAVMs as mutations in this pathway are correlated with AVMs in multiple organs in human patients [40] . It was found that the TGF-b-activating integrin b8 has reduced expression in human BAVMs [41] . Local deletion of b8 in the brain reduces TGF-b activation and induces enlarged dysplastic capillaries similar to BAVMs. Furthermore, certain b8 single nucleotide polymorphisms in humans were found to correlate with disease progression, suggesting that lack of b8 contributes to BAVMs [41] .
The Notch pathway has been implicated in a variety of hereditary disorders including Alagille syndrome and patent ductus arteriosus. Alagille syndrome is a multisymptomatic disorder primarily characterized by a paucity of intrahepatic bile ducts in the liver. This disease has been linked to mutations in Jagged1 (Jag1; 95% of the cases) and in Notch2 (5% of the cases) [42] . The onset and cellular origin of the disease was not well understood until recently. Interestingly, deletion of Jag1 in vascular smooth muscle cells (SMCs) recapitulates Alagille's paucity of bile ducts [43 & ]. It was found that biliary progenitors were unable to organize into tubes in mutant animals, and instead remained in a single layer adjacent to the portal vein [43 & ]. This unexpected finding demonstrates an instructive role of the vasculature in liver/biliary duct morphogenesis, and provides a clear understanding as to the cellular origin of the disease.
Patent ductus arteriosus, the most common congenital heart defect found in humans, may also be caused by aberrant Notch signaling. Feng et al. [44 & ] developed a mouse model of patent ductus arteriosus by deletion of the Notch ligand Jag1 in vascular SMCs that results in lethality at P2. Immunofluorescence analysis shows that these mice have defects in SMC differentiation, particularly in the ductus arteriosus. The authors found that injection of indomethacin (an antiinflammatory drug used to inhibit prostanoids) rescues ductus arteriosus closure in approximately 50% of the SMC knockout mice [44 & ]. This study suggests that Jag1 is crucial for SMC differentiation that allows closure of the ductus arteriosus by SMC contraction.
HETEROTYPIC CELL INTERACTIONS IN VASCULAR DEVELOPMENT
Vascular morphogenesis requires the collaborative effort of multiple cell types. Supporting cells from many different lineages have been shown to enhance and direct vessel development in specific organ beds. Individual organs have distinct cell types that impose unique phenotypic characteristics to the endothelium; however, the molecular underpinnings are far from clear.
Recent literature highlights the contribution of macrophages to angiogenesis. Specialized macrophages called tumor-associated macrophages (TAMs) and Tie-2 expressing monocytes (TEMs) promote pathological tumor angiogenesis [45] . The discovery of proangiogenic macrophages launched interest in the role of these cells during normal developmental angiogenesis. Embryonic Tie2-positive monocytes were observed at active sites of angiogenesis in developing embryos, suggesting an active contribution to angiogenesis [46] . Furthermore, expression profiles of TEMs sorted from mammary tumors were compared with embryonic TEMs, which showed a significant overlap in expression [46] .
Whereas the above studies suggested a vague role for macrophages in vascular development, Fantin et al. [47 && ] determined that tissue macrophages specifically promote anastamosis. Yolk sac-derived macrophages in the developing hindbrain are found at points of bridging of endothelial tip cells. They accumulate at highest numbers when the vasculature is organizing a network at E11.5, suggesting that macrophages aid in the bridging of tip cells (Fig. 3) . Absence of yolk-sac macrophages in the PU.1-null mouse results in a reduced number of vascular intersections rather than number of tipcells. Furthermore, no reduction in VEGF levels was detected. Macrophage depletion shows a phenotype distinct from that of VEGF gradient defects, which reinforces the idea that macrophages aid endothelial cell anastomosis rather than promote sprouting [47 && ]. It has been proposed that lymphatic endothelium incorporates transdifferentiated macrophages into the endothelial wall. Gordon et al. [48] showed that although intimately localized, a macrophage/lymphatic transition cell was never observed and historical macrophage tracing never yielded lymphatic endothelium that was positive for the tracer. Macrophages do, however, influence lymphatic development. Loss of macrophages results in hyperplastic lymphatic vessels due to overproliferation of dermal lymphatic endothelium. These results indicate a directing role for macrophages in the size, shape and complexity of the developing vasculature.
Endothelial cells vary phenotypically from tissue to tissue due to their interactions with distinctcell types. Strikingly, the blood-brain barrier (BBB) requires endothelial cells to act as the major impediment to the passage of solutes from the blood, a process that depends on specialized, complex tight junctions and a lower rate of vesicular transport. Armulik et al. [49 & ] determined that this endothelial behavior is imposed, in part, by pericytes. Using two pericyte-deficient mouse models, it was found that a lack of pericytes was correlated with increased water content and accumulation of BBB-impermeable dyes in the brain (Fig. 3) . The increased BBB permeability was attributed to a defect in transcytosis of the endothelial cells. Analysis of microvascular fragments indicated that in the absence of endothelial-pericyte contact, lower levels of several endothelial BBB markers were noted [49 & ]. This data indicates for the first time that pericyte contact with endothelial cells induces changes in expression that induce specialized BBB endothelial phenotype.
Relationships between vessels and the organs they inhabit are reciprocal; just as parenchyma informs endothelial development, so too can endothelial cells direct organ differentiation. As previously mentioned, perturbation of vessel function by deletion of Jag1 in vascular smooth muscle cells disrupts the differentiation of bile ducts in the liver [42] . Correspondingly, adipose tissue development, as studied in the postnatal epididymal adipose tissue (EAT) model, is dependent on preceding angiogenesis. When angiogenesis in EAT is blocked by injection of a VEGF-Trap, adipocytes are of much smaller size and fail to cover the entire vascular network [50] (Fig. 3) . This research points to an important role held by the vasculature in the regulation of tissue growth and reciprocal instructive interactions.
CONCLUSION
During the last two years, a significant number of advancements have been achieved using mouse models. In particular, signaling experiments have left the culture dish to find a home in a whole organism. However, weaving together a multitude of signaling pathways to a point wherein a complicated input translates to a known cellular output will progressively impose additional challenges. Yet, it is remarkable that using the mouse model major strides have been made toward understanding vascular lumen formation. Future progress in this field also hinges on the development of cell-culture systems that are amenable to concurrent live imaging and flow. Vascular diseases often present no symptoms until adulthood, although the disorder can originate from a developmental defect or genetic incident. Understanding the molecular and cellular origins of vascular diseases will expand the toolbox available for diagnosis and treatment of affected patients. Equally important, this research is critical to our understanding of fundamental developmental processes. In particular, the vasculature appears to hold the ability to impart inductive signals to the adjacent parenchyma and directly contribute to the ultimate three-dimentional architecture of an organ.
Finally, the discovery that certain regions of endothelium have hemogenic potential has opened a pandora's box: what exactly are the elements that specify hemogenic capacity? Can this capacity be regained? Recent findings suggest a specialized transcription machinery that is distinct to hemogenic endothelium. Reproduction of this capacity ex vivo holds significant therapeutic value.
